CaLIPSO Study Group

United States

Kevin W. Nash, NorthShore University HealthSystem, Evanston, IL; Marwan O. Kaskas, Northwest Louisiana Nephrology LLC, Shreveport, LA ; Edouard Rene Martin, South Florida Research Institute, Lauderdale Lakes, FL; Marializa Victorino Bernardo, Southwest Houston Research, Ltd, Houston, TX ; Bhasker Mehta, Arlington Nephrology, Arlington, TX; George Hon, Kidney Wellness Institute, Long Beach, CA; Jill Marie Meyer, California Institute of Renal Research, Inc, Chula Vista, CA ; Dylan Lior Steer, California Institute of Renal Research, San Diego, CA; Premila Bhat, Ridgewood Dialysis Center, Ridgewood, NY; Toros Kapoian, Dialysis Clinic, Inc, North Brunswick, NJ; James Sullivan III, Sierra Nevada Nephrology Consultants, Reno, NV; Nelson P. Kopyt, Northeast Clinical Research Center, LLC, Bethlehem, PA; Steven Zeig, Pines Clinical Research, Inc, Hollywood, FL; Juan Mauricio Cuellar, AMPM Research Clinic, Miami Gardens, FL; Robert Isaac Lynn, DaVita Clinical Research, Bronx, NY; David A. Roer, Nephrology and Hypertension Associates, PC, Middlebury, CT; Nirav Dinesh Gandhi, Southern California Medical Research Center, La Palma, CA; Kenneth Scott Kleinman, Nephrology Education Services and Research Inc, Tarzana, CA; Ramon Narciso Arenas Guadiz, North America Research Institute, Lynwood, CA; Jieshi Yan, Simi Valley Dialysis, Simi Valley, CA; Melvin M. Seek, Discovery Medical Research, Inc, Ocala, FL; William Tracy Durham, Mountain Kidney and Hypertension Associates, PA, Asheville, NC; Daniel A. Rakowski, TKS Research, PLLC, Chesapeake, VA; Joel Michels Topf, St Clair Nephrology Research, Roseville, MI; Lawrence Marshall Lehrner, South Las Vegas Dialysis Center, Las Vegas, NV; Stephen Lawrence Graham, Beverly Hills Dialysis Center, Beverly Hills, CA; Aamir Z. Jamal, North American Research Institute, San Dimas, CA; Osman Saleem Khawar, California Institute of Renal Research, Escondido, CA; Sohan Dua, Valley Renal Medical Group, Northridge, CA; Ramachandra V. Patak, California Medical Research Associates Inc, Northridge, CA; Jesus Ovidio Navarro, Genesis Clinical Research, LLC, Tampa, FL; Braxter Pleasant Irby, Jr, McComb Dialysis, McComb, MS; Sudhir Shyam Joshi, National Institute of Clinical Research, Bakersfield, CA; Riad Y Darwish, American Institute of Research, Whittier, CA; Michael S. Anger, Western Nephrology and Metabolic Bone Disease, PC, Westminster, CO; Kamal V. Gandhi, Renal Consultants Medical Group, Granada Hills, CA; Fahd Al-Saghir, Michigan Kidney Consultants, PC, Pontiac, MI; Bun Jim, US Renal Care, Bronx, NY; Harmeet Singh, Western Nephrology, Arvada, CO.

Spain

María Montserrat Belart Rodríguez, Sistemes Renals SA, Lleida; Emilio González Parra, Fundacion Jimenez Diaz, Madrid; Antonio Francisco Planas Pons, Hospital Comarcal de Inca, Inca; Silvia Collado Nieto, Hospital del Mar, Barcelona; José Antonio Ibeas López, Corporacio Sanitaria Parc Tauli, Sabadell; Joaquín Manrique Escola, Complejo Hospitalatorio de Navarra, Pamplona; Gonzalo Gómez Marques, Hospital Son Espases, Palma; Joan Manuel Díaz Gómez, Fundacio Puigvert, Barcelona; Mariano Rodríguez Portillo, Hospital Universitario Reina Sofia, Cordoba; Juan Manuel Buades Fuster, Hospital Son Llatzer, Palma de Mallorca; Natalia Ramos Terrades, Hospital Universitari Vall d'Hebron, Barcelona; Isabel Martínez Fernández, Hospital de Galdakao-Usansolo, Galdakao; María Jesús Puchades Montesa, Hospital Clinico Universitario de Valencia, Valencia; Pablo Molina Vila, Hospital Universitario Dr Peset, Valencia; Meritxell Ibernón Vilaro, Hospital Sant Joan Despi Moises Broggi, Sant Joan Despi ; Mercedes Salgueira Lazo, Hospital Universitario Virgen de la Macarena, Sevilla; Luis Miguel

Lou Arnal, Hospital Universitario Miguel Servet, Zaragoza; Jesús Calviño Varela, Hospital Lucus Augusti, Lugo; José Felipe Sarró Sobrín, Hospital Universitario Arnau de Vilanova, Lleida; Francisco Maduell Canals, Hospital Clinic, Barcelona.

United Kingdom
Smeeta Sinha, Salford Royal NHS Foundation Trust, London; Sandip Mitra (former investigator: Alastair Hutchinson), Central Manchester University Hospitals, Manchester; Kevin S. Eardley, Royal Shrewsbury Hospital, Shrewsbury; Gowrie Balasubramaniam, Southend University Hospital NHS Foundation Trust, Westcliff on Sea; Ashraf Mikhail, Morriston Hospital, Morriston; Tarun Bansal, St Luke's Hospital, Bradford.

Other Important Participants in the Study
Contract Research Organization: Clinipace GmbH, Eschborn, Germany
Central Imaging: Intrinsic Imaging, LLC Bolton, MA

Supplemental Table 1. Demographic and baseline characteristics for patients included or not included in the DXA modified intention-to-treat (DXA mITT) population.

Characteristics	Patients Included in DXA mITT Population (*n*=202[a])	Patients Not Included in DXA mITT Population (*n*=71[b])
Age, yr		
Mean±SD	64±9	64±8
Median (range)	64 (35–83)	63 (45–80)
Age >55 yr, *n* (%)	165 (82)	58 (82)
Female, *n* (%)	75 (37)	32 (45)
Hispanic or Latino, *n* (%)	76 (38)	23 (32)
Race, *n* (%)[c]		
White	147 (73)	41 (58)
Black	39 (19)	22 (31)
Asian	8 (4)	2 (3)
Other	2 (1)	1 (1)
Not reported	7 (3)	5 (7)
Body mass index		
Mean±SD (kg/m^2)	28.9±6.1	29.2±6.4
>19 kg/m^2	195 (97)	68 (96)
Dialysis vintage, mo		
Mean±SD	53±48	60±72
Median (range)	41 (6–339)	42 (7–521)
Relevant medical history, *n* (%)		
Osteoporosis	10 (5)	2 (3)
Fractures	10 (5)	2 (3)
Parathyroidectomy	3 (1)	1 (1)
Hyperparathyroidism	136 (67)	49 (69)
Concomitant medication use, *n* (%)		
Activated vitamin D	125 (62)	50 (70)
Bisphosphonates	3 (1)	1 (1)
Calcimimetics	70 (35)	30 (42)
Calcium supplementation	81 (40)	27 (38)
Noncalcium-based phosphate binders	137 (68)	52 (73)
Warfarin	21 (10)	5 (7)
BMD at baseline, mean±SD		
Total hip (g/cm^2)	0.829±0.170 (n=201)	0.816±0.178 (n=54)
Femoral neck (g/cm^2)	0.744±0.157 (n=202)	0.735±0.160 (n=54)

DXA, dual x-ray absorptiometry; BMD, bone mineral density.

[a]Patients who were randomized, received at least one dose of study treatment (SNF472 or placebo), and had an evaluable DXA scan both at baseline and postbaseline (week 52 or early termination).

[b]Patients who were randomized and received at least one dose of study treatment but were not included in the DXA mITT population.

[c]A patient could select more than one option for race.